LESLIE BEBB: Open Payments
NPI 1962699389 · HARTFORD, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$862 in 45 payments from 16 companies in 2025. Trend: 2023 $783 · 2024 $729 · 2025 $862
Food & beverage: $862
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $170 |
| ABBVIE INC. | 16 | $136 |
| Janssen Biotech, Inc. | 3 | $75 |
| Novo Nordisk Inc | 2 | $67 |
| Gilead Sciences, Inc. | 3 | $67 |
| Phathom Pharmaceuticals, Inc. | 5 | $56 |
| Madrigal Pharmaceuticals | 1 | $46 |
| Aimmune Therapeutics, Inc. | 1 | $34 |
| Amgen Inc. | 1 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $30 |
Products named: ENTYVIO, TREMFYA, Wegovy, VOQUEZNA, RINVOQ, LINZESS, REZDIFFRA, ZENPEP.
Industry payments across CT — which companies pay providers there.
